Roundtable Prostate Cancer
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.